Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized controlled trial to compare efficacy and safety between erlotinib and
gefitinib in advanced NSCLC harboring EGFR exon 19 or 21 mutations.Eligible patients were
randomized to receive erlotinib or gefitinib in any line settings.The primary endpoint was
progression-free survival (PFS).
Phase:
Phase 3
Details
Lead Sponsor:
Chinese Society of Lung Cancer
Collaborators:
Guangdong General Hospital Guangdong Provincial People's Hospital
Treatments:
Erlotinib Hydrochloride Gefitinib Molecular Mechanisms of Pharmacological Action